170 related articles for article (PubMed ID: 33770721)
21. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
[No Abstract] [Full Text] [Related]
22. Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [
Zha Z; Choi SR; Ploessl K; Alexoff D; Zhao R; Zhu L; Kung HF
Bioconjug Chem; 2021 May; 32(5):1017-1026. PubMed ID: 33872489
[TBL] [Abstract][Full Text] [Related]
23. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
24. Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity.
Mueller D; Klette I; Baum RP; Gottschaldt M; Schultz MK; Breeman WA
Bioconjug Chem; 2012 Aug; 23(8):1712-7. PubMed ID: 22755505
[TBL] [Abstract][Full Text] [Related]
25. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
26. High-Yielding Radiosynthesis of [
Zhang X; Liu F; Payne AC; Nickels ML; Bellan LM; Manning HC
Mol Imaging Biol; 2020 Oct; 22(5):1370-1379. PubMed ID: 32632739
[TBL] [Abstract][Full Text] [Related]
27. An
Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
[TBL] [Abstract][Full Text] [Related]
28. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.
Baur B; Solbach C; Andreolli E; Winter G; Machulla HJ; Reske SN
Pharmaceuticals (Basel); 2014 Apr; 7(5):517-29. PubMed ID: 24787458
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.
Läppchen T; Kiefer Y; Holland JP; Bartholomä MD
Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066
[TBL] [Abstract][Full Text] [Related]
31. Enhancing capacity and synthesis of [68Ga]68-Ga-PSMA-HBED-CC with the lyophilized ready-to-use kit for nuclear pharmacy applications.
Golan H; Esa M; Moshkoviz K; Feldhaim A; Hoch B; Shalom E
Nucl Med Commun; 2020 Sep; 41(9):986-990. PubMed ID: 32796488
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.
Weineisen M; Simecek J; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2014 Dec; 4(1):63. PubMed ID: 26116124
[TBL] [Abstract][Full Text] [Related]
33. Automated synthesis of
Sørensen MA; Andersen VL; Hendel HW; Vriamont C; Warnier C; Masset J; Huynh THV
J Labelled Comp Radiopharm; 2020 Jun; 63(8):393-403. PubMed ID: 32374450
[TBL] [Abstract][Full Text] [Related]
34. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
35. Cationic eluate pretreatment for automated synthesis of [⁶⁸Ga]CPCR4.2.
Martin R; Jüttler S; Müller M; Wester HJ
Nucl Med Biol; 2014 Jan; 41(1):84-9. PubMed ID: 24120219
[TBL] [Abstract][Full Text] [Related]
36.
Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T
Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
39. Automated radiolabelling of [
van Brandwijk EA; Aalbersberg EA; Hosseini AS; Huitema ADR; Hendrikx JJMA
EJNMMI Radiopharm Chem; 2024 Apr; 9(1):31. PubMed ID: 38632189
[TBL] [Abstract][Full Text] [Related]
40. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
